论文部分内容阅读
目的研究99mTc标记抗人胰腺癌单克隆抗体SZ-121在荷人胰腺癌裸鼠体内的显像及生物分布,探讨其用于胰腺癌早期诊断的可行性。方法采用皮下种植法建立荷人胰腺癌裸鼠移植瘤模型,以2-亚氨基噻吩盐酸盐(2-IT)修饰SZ-121,99mTc-葡庚糖酸钠(GH)配体交换法标记SZ-121,经裸鼠尾静脉注入99mTc-SZ-121后1、4h对裸鼠进行γ显像,于24h测定荷瘤小鼠体内组织的放射性分布。结果γ显像及生物分布显示,99mTc-SZ-121被静脉注入荷瘤鼠后1h,肿瘤即清晰显影,随时间延长趋于增浓,且瘤组织与非瘤组织的放射性比值(T/NT)也逐渐增高,肿瘤每克组织百分注射剂量率(%IDPg)均高于注射99mTc-IgG的对照组(P<0.05)。结论99mTc-SZ-121具有活体内定位导向能力,显像时间短,可能是一种有前途的胰腺癌显像剂。
Objective To study the imaging and biodistribution of 99mTc-labeled anti-human pancreatic cancer monoclonal antibody SZ-121 in human pancreatic cancer-bearing nude mice and to explore its feasibility for early diagnosis of pancreatic cancer. Methods The xenografted model of human pancreatic cancer in nude mice was established by subcutaneous implantation. The SZ-121 and 99mTc-glucoheptonate (GH) ligand exchange method was labeled with 2-iminothiophene hydrochloride (2-IT) SZ-121 was injected into 99mTc-SZ-121 via the caudal vein of mice, γ imaging was performed on the nude mice at 1 and 4 h, and the radioactivity distribution in vivo was measured at 24h. Results γ imaging and biodistribution of 99mTc-SZ-121 showed that the tumors were clearly developed at 1 h after tumor-bearing injection of 99mTc-SZ-121, and tended to be enriched with the passage of time. The ratio of tumor to non-tumor tissues (T / NT ) Also increased gradually, and the percentage of tumor per gram of injection rate (% IDPg) was higher than that of 99mTc-IgG injection group (P <0.05). Conclusion 99mTc-SZ-121 has the ability of targeting in vivo and short imaging time, which may be a promising imaging agent for pancreatic cancer.